Testing a new drug before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer at stage IB, II, or IIIA to IIIB.
- You are scheduled for surgery to remove the cancer.
- You have not had chemotherapy or radiation before this trial.
- You are not pregnant or breastfeeding.
- Your heart, kidneys, and other organs are working well enough for the study treatment.
- You do not have other active cancers or conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new immunotherapy drug (ivonescimab or penpulimab) to standard chemotherapy before surgery helps people with early-stage lung cancer. It's for people whose cancer can be surgically removed and who haven't had treatment yet.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This Phase 3 trial tests ivonescimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). It may help people by improving how well the cancer responds, especially in tumors with PD-L1 activity, but you must meet specific medical and testing requirements.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.